Today: 30 June 2026
Applied Materials stock slides as chip-tool selloff deepens; KLA tumble sets the tone

Applied Materials stock slides as chip-tool selloff deepens; KLA tumble sets the tone

New York, January 30, 2026, 12:31 PM EST — Regular session

  • Shares of Applied Materials dropped roughly 3% amid a broad sell-off in chip-equipment stocks.
  • KLA plunged over 12%, pulling its peers down with it.
  • Investors are zeroing in on the upcoming earnings reports to get a better handle on 2026 wafer-fab spending.

Applied Materials (AMAT) dropped 3.1% to $330.76 during midday trading Friday, deepening losses across chipmaking-tool shares.

This shift is crucial as investors pin their hopes on earnings season to gauge wafer fabrication equipment spending — the capital chipmakers allocate for the machinery that crafts chips on silicon wafers.

Spending on data center expansions and AI chips has long been a cornerstone trade. So when a major supplier falters, the ripple effects hit fast—and often hard.

KLA shares tumbled 12.8%, with Lam Research sliding 2.3% and ASML down 1.4%. The VanEck Semiconductor ETF and iShares Semiconductor ETF both dropped roughly 2% to 2.5%, dragging the S&P 500 ETF and Nasdaq 100 tracker lower as well.

KLA reported earnings late Thursday that beat Wall Street estimates and projected March-quarter results above consensus. Still, the stock slipped after the announcement. “The stock had already sprinted into the print,” noted Michael Ashley Schulman of Running Point Capital Advisors, who described the outlook as “steady growth rather than renewed acceleration.” Reuters

Lam’s update earlier this week outperformed forecasts, buoyed by a strong outlook. “Entering 2026, our expanding product and services portfolio is enabling the market’s transition to smaller, more complex three-dimensional devices and packages,” CEO Tim Archer said. Reuters

In Europe, ASML reported record fourth-quarter orders and raised its 2026 sales forecast, despite analysts questioning if it can keep up with demand. The company also announced job cuts. CEO Christophe Fouquet said they aim to “boost… our engineering capability, our innovation engine,” after years dealing with increasing complexity. Reuters

Applied Materials filed its annual proxy this week, scheduling the shareholder meeting for March 12 in Santa Clara, California. The document covers votes on directors, an advisory “say-on-pay” proposal, and auditor ratification for KPMG LLP. It also spotlighted progress on the EPIC Center project in Silicon Valley, expected to start operations in 2026. Stock Titan

Traders are shifting focus from proxy paperwork to the next big trigger: earnings and guidance. The key issue—will demand for foundry and logic (contract chipmaking and processor production) plus memory hold up after the recent surge in the sector?

The setup isn’t straightforward. Zacks pointed out this week that Applied Materials has outperformed its semiconductor peers over the last six months, but it also highlighted export restrictions, tensions with China, a sluggish memory market recovery, and rising costs as significant risks that could hit hard when expectations run high.

If the sector sticks to “steady” growth instead of faster gains, investors might continue pulling back with every report. Policy risks linger, too—U.S. restrictions on advanced tech exports to China remain a key wild card for tool demand.

Applied Materials is set to release its fiscal first-quarter results on Feb. 12. Investors will be watching closely for updates on the company’s outlook and any shifts in customer spending plans through the remainder of 2026.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
C3.ai stock price slips in premarket as Automation Anywhere merger-talk report lingers
Previous Story

C3.ai stock price slips in premarket as Automation Anywhere merger-talk report lingers

Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday
Next Story

Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday

Go toTop